OBI Pharma - Asset Resilience Ratio

Latest as of September 2025: 17.59%

OBI Pharma (4174) has an Asset Resilience Ratio of 17.59% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 4174 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

NT$673.70 Million

≈ $21.23 Million USD Cash + Short-term Investments

Total Assets

NT$3.83 Billion

≈ $120.64 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2011–2024)

This chart shows how OBI Pharma's Asset Resilience Ratio has changed over time. See OBI Pharma (4174) balance sheet quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down OBI Pharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 4174 company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$673.70 Million	17.59%
Total Liquid Assets	NT$673.70 Million	17.59%

Asset Resilience Insights

Good Liquidity Position: OBI Pharma maintains a healthy 17.59% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

OBI Pharma Industry Peers by Asset Resilience Ratio

Compare OBI Pharma's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Cyclacel Pharmaceuticals Inc NASDAQ:CYCC	Biotechnology	-55.36%
Krystal Biotech Inc NASDAQ:KRYS	Biotechnology	23.06%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for OBI Pharma (2011–2024)

The table below shows the annual Asset Resilience Ratio data for OBI Pharma.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	24.74%	NT$1.40 Billion ≈ $44.07 Million	NT$5.65 Billion ≈ $178.12 Million	-8.86pp
2023-12-31	33.60%	NT$1.88 Billion ≈ $59.33 Million	NT$5.60 Billion ≈ $176.55 Million	+33.13pp
2022-12-31	0.47%	NT$31.46 Million ≈ $991.23K	NT$6.63 Billion ≈ $209.00 Million	-2.69pp
2021-12-31	3.16%	NT$141.77 Million ≈ $4.47 Million	NT$4.49 Billion ≈ $141.36 Million	-4.02pp
2020-12-31	7.18%	NT$383.53 Million ≈ $12.08 Million	NT$5.34 Billion ≈ $168.23 Million	+7.16pp
2019-12-31	0.02%	NT$1.39 Million ≈ $43.92K	NT$5.66 Billion ≈ $178.42 Million	-38.95pp
2017-12-31	38.97%	NT$2.02 Billion ≈ $63.72 Million	NT$5.19 Billion ≈ $163.51 Million	+1.68pp
2016-12-31	37.29%	NT$2.36 Billion ≈ $74.34 Million	NT$6.33 Billion ≈ $199.37 Million	+4.71pp
2012-12-31	32.58%	NT$284.81 Million ≈ $8.97 Million	NT$874.17 Million ≈ $27.54 Million	-41.39pp
2011-12-31	73.97%	NT$386.65 Million ≈ $12.18 Million	NT$522.72 Million ≈ $16.47 Million	--

pp = percentage points

About OBI Pharma

TWO:4174 Taiwan Biotechnology

Market Cap

$116.20 Million

NT$3.69 Billion TWD

Market Cap Rank

#18718 Global

#1035 in Taiwan

Share Price

NT$28.05

Change (1 day)

+0.72%

52-Week Range

NT$23.25 - NT$50.50

All Time High

NT$743.00